Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

Study Description

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

Background:

• Some illnesses, such as schizophrenia, have effects on brain cells called dopamine receptors, which are required for normal brain function. People with schizophrenia have difficulty thinking and experience hallucinations and delusions. Medications that change brain dopamine receptors can decrease these hallucinations and delusions.
• The cause of schizophrenia and its association with brain dopamine receptors is not known but may be clarified by studying dopamine receptors in people who have dopamine disorders (such as schizophrenia) and those who do not. Researchers are interested in studying the dopamine system to gain a better idea of how dopamine disorders develop, which may lead to better medical care for people with schizophrenia.

Objectives:

- To study the amount and distribution of two types of dopamine receptors.

Eligibility:

• Individuals between the ages of 18 and 60 who have schizophrenia.
• Healthy volunteers between the ages of 18 and 90.

Design:

• Participants will undergo a full screening, with physical and psychological history, a neurological examination, and blood and urine samples.
• Participants will have a blood flow map of the brain recorded with a positron emission tomography (PET) brain scan. A magnetic resonance imaging (MRI) scan will also be performed to determine brain anatomy.
• To study the amount and distribution of dopamine receptors in the brain, participants will receive a small amount of a radioactive chemical in the vein, followed by a PET scan.
• The procedure will be performed twice in two separate sessions, once for [18F]fallypride and once for [11C]NNC-112.

Condition or disease
Schizoaffective Disorder; Schizophrenia

  Show Detailed Description

Study Design

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Observational
Estimated Enrollment :	330 participants
Time Perspective:	Other
Official Title:	Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
Study Start Date :	July 17, 2009

Groups and Cohorts

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Outcome Measures

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Regional binding potentials of [11C]NNC-112 and [18F]Fallypride

Eligibility Criteria

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 90 Years (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

• INCLUSION CRITERIA:
• Subjects will be recruited among individuals volunteering for NIH protocol 95-M-0150 A Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings (PI: Daniel Weinberger, M.D.), NIH protocol 00-M-0085 Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers with 3.0 Tesla MRI and Magnetoencephalography. (P.I.: Venkata Mattay, MD) or NIH protocol 89-M-0160 Inpatient Evaluation of Neuropsychiatric Patients (PI: Jose Apud, M.D. Ph.D).
• Only adult subjects who are able to provide informed consent will be studied.
• Patients will be between 18 and 60 years of age. Healthy controls will be matched by age and sex to the patients.
• Control subjects must be healthy based on history, laboratory and physical exam obtained through the above mentioned protocols and will be included up to the age of 90 years.

EXCLUSION CRITERIA: (for patients and controls except where indicated)

• Subjects will be excluded if they don t fit the study requirements regarding age, ability to provide informed consent, absence of significant general medical, neurological or psychiatric disorders (except the disorder object of study), or intake of substances that interfere with central dopaminergic signaling.
• Pregnant or breast feeding.
• Current psychiatric illness except for patients with schizophrenia, schizoaffective disorder or other psychotic disorder
• Current or prior use (within 4 weeks) of substances that interfere with central dopaminergic signaling (e.g. antipsychotics, dopamine receptor agonists, anticholinergics, MAO-B inhibitors)
• History of any (excepting nicotine- related) DSM5-defined substance dependence).
• Cumulative lifetime history of any (excepting nicotine -related) DSM5-defined mild substance use disorder (or any DSM-IV-defined substance abuse
• Controls with current psychiatric illness other than schizophrenia, schizoaffective disorder, or other psychotic disorder
• Secondary causes of schizophrenia-like syndromes, e.g. amphetamine abuse, brain infarction, tumor, or trauma
• Neurological disorders except those of exclusively peripheral location
• Significant prior or current substance abuse, severe systemic disease, hypothyroidism not compensated by medication
• Laboratory tests with clinically significant abnormalities
• History of a significantly abnormal EEG, cranial CT or MRI
• Conditions that increase risk for MRI (pacemaker devices, ferromagnetic metal implants, etc.)
• Prior participation in other research protocols such that radiation exposure would exceed the annual NIH RSC limits
• Any medical condition that, in the opinion of the investigators, would interfere with the safe conduct of the study.

Contacts and Locations

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Contacts

Contact: Jasmin Czarapata, Ph.D.	(301) 435-7645	js733c@nih.gov
Contact: Karen F Berman, M.D.	(301) 496-7603	bermank@mail.nih.gov

Locations

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike	Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 prpl@cc.nih.gov

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

Investigators

Principal Investigator:	Karen F Berman, M.D.	National Institute of Mental Health (NIMH)

More Information

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:

NIH Clinical Center Detailed Web Page 

Publications:

Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000 Oct;157(10):1552-62.

Tan HY, Callicott JH, Weinberger DR. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex. 2007 Sep;17 Suppl 1:i171-81. Review.

Weinberger DR. Schizophrenia drug says goodbye to dopamine. Nat Med. 2007 Sep;13(9):1018-9.

ClinicalTrials.gov Identifier:	NCT00942981 History of Changes
Other Study ID Numbers:	090176; 09-M-0176
First Posted:	July 21, 2009
Last Update Posted:	March 29, 2018
Last Verified:	September 29, 2017

Keywords provided by National Institutes of Health Clinical Center (CC):

PET Study; (18F) Fallypride; (11C)NNC-112; Schizoaffective Disorder	Schizophrenia; Healthy Volunteer; HV

Additional relevant MeSH terms:

Schizophrenia; Psychotic Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Dopamine; Cardiotonic Agents; Sympathomimetics	Autonomic Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Dopamine Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Protective Agents